CJC-1295

§1 Definition

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It exists in two commercially relevant forms with very different pharmacokinetics: without DAC (also sold as "Mod GRF 1-29"), with a half-life of roughly 30 minutes, and with DAC (Drug Affinity Complex), which binds serum albumin and extends the half-life to 5.8-8.1 days. Not FDA-approved for any use; a 2006 human trial of the DAC form was published, but a separate clinical program was terminated after a participant death.

§2 Evidence tier and regulatory status

Not FDA-approved for any use. Nominated to FDA's 503A Category 2 bulk-substances list (substances presenting significant safety risks); the nomination was withdrawn and CJC-1295 was removed from the Category 2 list in September 2024. FDA's Pharmacy Compounding Advisory Committee reviewed CJC-1295 (across its free-base, acetate, DAC free-base, DAC acetate, and DAC-TFA forms) on December 4, 2024, and voted against adding it to the 503A Positive Bulks list, citing nonclinical toxicity findings (pituitary-cell DNA damage and injection-site necrosis in animal studies), immunogenicity risk, and what FDA termed an "unresolved cardiac signal" from a 2006 clinical trial that was terminated after a participant death. This narrative is corroborated across independent secondary summaries and a confirmed FDA docket number (FDA-2024-N-4777); the exact primary-document quote language could not be independently extracted from FDA's PDF in this research pass.

§3 Documented dosing

§4 Reconstitution math

No FDA-approved product exists, so no FDA-labeled reconstitution protocol exists either. General lyophilized-peptide reconstitution practice is commonly applied by research users, but this is not backed by a compound-specific clinical or regulatory source.

§5 What the research shows

A separate published trial (Teichman et al., J Clin Endocrinol Metab 2006) examined CJC-1295-with-DAC's growth-hormone and IGF-1 stimulating effects in two randomized, placebo-controlled, double-blind ascending-dose studies (28 and 49 days) in healthy adults ages 21-61, describing it as "safe and relatively well tolerated" particularly at 30-60 mcg/kg, with dose-dependent GH increases (2-10x) lasting 6+ days and IGF-1 increases (1.5-3x) lasting 9-11 days. This trial is not included as a table row above because secondary sources report inconsistent participant counts (21 vs 65) that this research pass could not resolve against the paywalled primary text — no specific n is presented rather than guessing between them.

§6 Safety and reported adverse effects

No published adverse-effect data located.

No detailed adverse-event incidence table was extracted from the Teichman 2006 trial in this research pass (would require full-text access). What is documented: the 2006 ConjuChem trial death described above, and FDA's 2024 nonclinical toxicology findings (pituitary-cell DNA damage, injection-site necrosis) — these are animal/nonclinical findings, not human incidence data.

§7 Storage and handling

Lyophilized

No published data located.

Reconstituted

No published data located.

§8 Sourcing considerations

• Confirm which variant is actually being sold — without-DAC ("Mod GRF 1-29") and with-DAC products have very different half-lives and are not interchangeable, but listings do not always distinguish them clearly.
• Since CJC-1295 is not FDA-approved for any use, verify the seller provides a Certificate of Analysis from an independent, named third-party lab.
• Be aware FDA's 2024 review cited unresolved safety questions (nonclinical toxicity findings and an unresolved cardiac signal from a terminated human trial) when declining to add this compound to its compounding-eligible substances list.

§9 FAQ

§10 Sources